Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Abacavir
Drug ID BADD_D00008
Description Abacavir (ABC) is a powerful nucleoside analog reverse transcriptase inhibitor (NRTI) used to treat HIV and AIDS. Chemically, it is a synthetic carbocyclic nucleoside and is the enantiomer with 1S, 4R absolute configuration on the cyclopentene ring. In vivo, abacavir sulfate dissociates to its free base, abacavir.
Indications and Usage For the treatment of HIV-1 infection, in combination with other antiretroviral agents.
Marketing Status Prescription
ATC Code J05AF06
DrugBank ID DB01048
KEGG ID D07057
MeSH ID C106538
PubChem ID 441300
TTD Drug ID D0A4IJ
NDC Product Code 50268-049; 55111-920; 65862-073; 0121-0897; 72865-167; 0904-6874; 70518-1274; 31722-562; 31722-557; 69097-514; 64380-717
Synonyms abacavir | 1592U89 | abacavir sulfate | Ziagen | (1S,4R)-4-(2-amino-6-(cyclopropylamino)-9H-purin-9-yl)-2-cyclopentene-1-methanol | abacavir succinate
Chemical Information
Molecular Formula C14H18N6O
CAS Registry Number 136470-78-5
SMILES C1CC1NC2=C3C(=NC(=N2)N)N(C=N3)C4CC(C=C4)CO
Chemical Structure
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Depressed mood19.15.02.001--Not Available
Depression19.15.01.001--
Dermatitis23.03.04.002--Not Available
Diarrhoea07.02.01.001--
Discomfort08.01.08.003--Not Available
Dizziness02.01.02.004; 17.02.05.003; 24.06.02.0070.037779%
Drug eruption08.01.06.015; 10.01.01.005; 23.03.05.0010.018890%Not Available
Drug hypersensitivity10.01.01.001--Not Available
Dyspnoea02.01.03.002; 22.02.01.004--
Erythema multiforme10.01.03.015; 23.03.01.003--
Fatigue08.01.01.002--
Feeling abnormal08.01.09.014--Not Available
Gamma-glutamyltransferase increased13.03.01.011--
Gastritis07.08.02.001--
Gastroenteritis07.19.03.001; 11.01.07.004--Not Available
Gastrointestinal disorder07.11.01.001--Not Available
Gastrointestinal pain07.01.05.005--
Haemorrhage intracranial17.08.01.008; 24.07.04.0030.004928%
Headache17.14.01.0010.028334%
Hepatic failure09.01.03.002--
Hepatic steatosis09.01.07.003; 14.08.04.005--Not Available
Hepatitis09.01.07.004--Not Available
Hepatitis B09.01.09.003; 11.05.06.002--
Hepatomegaly09.01.05.001--Not Available
Hypercholesterolaemia14.08.01.001--Not Available
Hyperglycaemia05.06.02.002; 14.06.02.002--
Hyperlactacidaemia14.01.01.006--Not Available
Hypersensitivity10.01.03.0030.066114%
Hypertriglyceridaemia14.08.02.001--
Hypotension24.06.03.002--
The 2th Page    First    Pre   2 3 4 5    Next   Last    Total 5 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene